Abstract

Loss of BRCA2 affects genome stability and is deleterious for cellular survival. Using a genome-wide genetic screen in near-haploid KBM-7 cells, we show that tumor necrosis factor-alpha (TNFα) signaling is a determinant of cell survival upon BRCA2 inactivation. Specifically, inactivation of the TNF receptor (TNFR1) or its downstream effector SAM68 rescues cell death induced by BRCA2 inactivation. BRCA2 inactivation leads to pro-inflammatory cytokine production, including TNFα, and increases sensitivity to TNFα. Enhanced TNFα sensitivity is not restricted to BRCA2 inactivation, as BRCA1 or FANCD2 inactivation, or hydroxyurea treatment also sensitizes cells to TNFα. Mechanistically, BRCA2 inactivation leads to cGAS-positive micronuclei and results in a cell-intrinsic interferon response, as assessed by quantitative mass-spectrometry and gene expression profiling, and requires ASK1 and JNK signaling. Combined, our data reveals that micronuclei induced by loss of BRCA2 instigate a cGAS/STING-mediated interferon response, which encompasses re-wired TNFα signaling and enhances TNFα sensitivity.

The loss of homologous recombination (HR) genes such as BRCA1 and BRCA2 is deleterious to the survival of normal cells, yet it is tolerated in cancer cells. Here the authors identify TNFα signaling as a determinant of viability in BRCA2- inactivated cancer cells.

Details

Title
BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity
Author
Heijink, Anne Margriet 1 ; Talens Francien 1 ; Jae, Lucas T 2 ; van Gijn Stephanie E 1 ; Fehrmann Rudolf S N 1 ; Brummelkamp Thijn R 3 ; van Vugt Marcel A T M 1 

 University of Groningen, Department of Medical Oncology, University Medical Center Groningen, Cancer Research Center Groningen, Groningen, The Netherlands (GRID:grid.4830.f) (ISNI:0000 0004 0407 1981) 
 Ludwig-Maximilians-Universität München, Gene Center and Department of Biochemistry, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X) 
 Netherlands Cancer Institute, Oncode Institute, Division of Biochemistry, Amsterdam, The Netherlands (GRID:grid.430814.a) ; Cancer Genomics Center, Amsterdam, The Netherlands (GRID:grid.430814.a) ; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria (GRID:grid.418729.1) (ISNI:0000 0004 0392 6802) 
Publication year
2019
Publication date
Jan 2019
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2165651746
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.